Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis.

Hu, Chuanpu; Vetter, Marion; Vermeulen, An; Ouellet, Daniele

Hu, Chuanpu; Vetter, Marion; Vermeulen, An; Ouellet, Daniele.

Afiliação

Hu C; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, PA, USA. CHu25@its.jnj.com.
Vetter M; Janssen Research & Development, LLC, PO Box 776, 1400 McKean Road, Spring House, PA, 19477, USA. CHu25@its.jnj.com.
Vermeulen A; Clinical Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.
Ouellet D; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium.

J Pharmacokinet Pharmacodyn ; 50(2): 133-144, 2023 04.

Article em En | MEDLINE | ID: mdl-36648595

Assuntos

Colite Ulcerativa; Humanos; Colite Ulcerativa/tratamento farmacológico; Anticorpos Monoclonais/farmacologia; Anticorpos Monoclonais/uso terapêutico; Resultado do Tratamento; Índice de Gravidade de Doença

Palavras-chave

Additivity; Model-informed drug development; NONMEM; Population pharmacokinetic/pharmacodynamic modeling; Synergy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google